Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

TRADE NEWS: Agilent Technologies Introduces HaloPlex Next-Generation Sequencing Panels Targeting Cancer and Inherited Diseases



  TRADE NEWS: Agilent Technologies Introduces HaloPlex Next-Generation
  Sequencing Panels Targeting Cancer and Inherited Diseases for Research

      Catalog and Custom Panels Enable Rapid, Targeted Genomics Analysis

Business Wire

SANTA CLARA, Calif. -- June 11, 2013

Agilent Technologies Inc. (NYSE: A) today introduced a new series of HaloPlex
next-generation sequencing panels targeting specific disease states. Two
catalog products, the HaloPlex Cancer Research Panel and the HaloPlex
Cardiomyopathy Research Panel, plus five predesigned research panels for
arrhythmia, ICCG genomic regions, X chromosome, Noonan syndrome, and
connective tissue disorders are now available. Used in combination with
Agilent’s SureDesign and SureCall software, the new panels enable laboratories
to perform integrated data analysis, mapping and reporting with greater
confidence, speed and flexibility.

“With the adoption of desktop sequencing, clinical research laboratories are
increasingly interested in panels with predesigned content for routine
analysis,” said Dr. Berivan Baskin, FACMG, FCCMG, clinical molecular
geneticist at Uppsala University Hospital, who worked with Agilent to develop
the panels. “These new HaloPlex panels, combined with Agilent’s analysis
software, provide comprehensive content with high levels of sensitivity and
specificity.”

“Clinical research laboratories commonly lack the time and resources necessary
to individually define disease-related genes and incorporate them into their
own custom sequencing panels,” said Jacob Thaysen, vice president and general
manager of Agilent’s Genomics Solutions Division. “So we have been working
closely with industry experts to develop these targeted disease panels to help
these laboratories dramatically improve their workflows and research
outcomes.”

HaloPlex target-enrichment solutions combine the speed and specificity of
polymerase chain reaction-based systems with the scalability and capture-size
flexibility of solution-based hybridization formats, eliminating the need for
library preparation. This streamlined sequence-selective solution for
next-generation sequencing helps to remove bottlenecks associated with
targeted resequencing and eliminates the need for expensive, dedicated
instrumentation or laborious protocols.

SureDesign and SureCall software programs are an integral part of Agilent’s
complete solutions for next-generation sequencing target enrichment.
SureDesign increases flexibility by allowing HaloPlex panel users to develop
custom panels and incorporate additional predesigned genes/regions of interest
to suit their laboratory’s individual needs. SureCall significantly reduces
the data analysis hurdles faced by researchers, enabling simple and intuitive
variant calling.

About Agilent in Genomics

Agilent Technologies Inc. is a global leader in target enrichment for
next-generation sequencing and genomic microarrays. The Agilent SureSelect and
HaloPlex target-enrichment systems enable researchers to easily choose which
segments of a genome to sequence, avoiding the time and expense needed to
sequence the entire genome. HaloPlex and its same-day sample-to-sequencer
workflow is well suited for next-gen desktop sequencers, whereas SureSelect’s
ability to accurately capture whole exomes and whole methylomes in a single
reaction pairs well with high-throughput next-gen sequencing systems. These
are just two products arising from Agilent’s expertise in synthesizing custom
complex mixtures of long oligonucleotides gained in microarray manufacturing.
Additional product lines built on this core technology include microarrays for
genome-wide measurement of gene expression and for comparative genomics
hybridization, as well as SureFISH, a highly specific and sensitive product
line for oligonucleotide flourescent in situ hybridization. In addition to
oligonucleotide-based products, Agilent offers a microfluidic bioanlyzer to
measure sample quality, a target-enrichment tool to speed next-gen sequencing,
and a full set of reagents, hardware, methods and bioinformatics software for
genomic experiments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company’s 20,500 employees serve customers
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news
is available at www.agilent.com/go/news.

Contact:

Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
susan_berg1@agilent.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement